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 ABSTRACT
Renal transplant in highly sensitised patients is 
associated with increased morbidity. The aim of this 
retrospective study was to evaluate the clinical evo-
lution of 30 highly sensitised deceased donor kidney 
transplants and the influence of different timing of 
B cell directed treatment and its importance in the 
outcome of these patients. All recipients had negative 
complement dependent lymphocytotoxicity cytotoxic 
T cell crossmatch and no identified anti human leu-
cocyte antigen class I donor specific antibodies. T 
cell flow crossmatch was performed within 24h of 
transplantation with serum obtained pretransplant 
(historic, recent or baseline). Posttransplant flow 
crossmatch were performed prospectively starting on 
the 3rd posttransplantation day. The immunosuppres-
sive regime included thymoglobulin, tacrolimus, 
mycofenolate mofetil and steroids.
Positive flow crossmatch occurred in 20/29 
patients by the 3rd posttransplantation day, and in 
17/27 patients after the 3rd posttransplantation day. 
All patients were started on intravenous immuno-
globulin before transplantation: in nine patients 
(group A) at 400mg/kg/day for five days; in the 
remaining 21 patients (group B), as a continued 
infusion of 2g/kg during 48h. In group A, Ritux-
imab was added only in the presence of antibody 
mediated rejection; in group B, introduced on the 
3rd posttransplantation day whenever a positive 
flow crossmatch (with serum obtained pre or post-
transplant) was reported. Antibody mediated 
rejection was observed in 44.4% of patients in 
group A, and 19% of those in group B. Mean 
follow -up was 12.2±5.5 months. Overall allograft 
survival was 76.6%, 81% in group B, and 66.6% 
in group A. At last follow up, mean serum crea-
tinine was 1.3±0.6 mg/dl.
Renal transplantation with pretransplant positive 
flow crossmatch is highly associated with antibody 
mediated rejection, despite introduction of intrave-
nous immunoglobulin pretransplantation. However 
high dose intravenous immunoglobulin for 48h plus 
Rituximab by the 3rd posttransplantation day reduce 
the incidence of antibody mediated rejection by 
more than 50% and allowed for allograft survival of 
81% at one year, with an excellent renal function.
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 INTRODUCTION
A positive reaction against human leucocyte anti-
gen (HLA) of donor in complement dependent lym-
phocytotoxicity (CDC) assay has been considered, 
since the 1969 Patel and Terasaki study1, as counter-
indication for kidney transplantation. More than one 
third of all patients awaiting a deceased donor 
kidney transplant are highly sensitised to HLA and 
sensitisation is a significant obstacle for success in 
kidney transplantation2. If transplanted, there is an 
increased risk of rejection and a low allograft sur-
vival1,3. Some transplantation units perform a T cell 
flow cytometric crossmatch (FXM) in sensitised 
patients or in potential second transplant patients 
before kidney transplantation. As it is a test with 
greater sensitivity than CDC crossmatch, these 
highly sensitised patients are destined to remain 
waitlisted for many years.
Since August 2007 Portuguese criteria for kidney 
transplantation require a recent negative T cell CDC 
crossmatch, and absence of identified anti HLA class 
I donor specific antibodies (DSA). T FXM with peak 
historic serum is performed retrospectively within 
the first 24 hours posttransplant. In this retrospec-
tive study, we report the follow up of 30 highly 
sensitised patients (PRA >70%) transplanted with a 
negative CDC crossmatch, absence of anti DSA, and 
various FXM pretransplant results and the main 
objective of this study was to evaluate the clinical 
outcome of these patients, and the influence of 
modifying the timing and indication of intravenous 
immunoglobulin (IVIG) and Rituximab. Prospective 
posttransplant determinations of FXM with donor 
cryopreserved cells and renal allograft biopsies were 
used to evaluate risk factors and immunosuppressive 
therapies.
 PATIENTS AND METHODS
 Study design
This was a retrospective study of 30 highly sen-
sitised patients receiving deceased donor kidney 
transplant in two Portuguese Transplantation Units 
August 2007 -September 2008. All patients had a 
negative T cell CDC crossmatch and no known pre-
formed class I anti DSA.
Clinical data included age, gender, race, mean 
haemodialysis time, HLA matches, donor character-
istics, mean cold ischaemia time, rejection episodes, 
and immunosuppression (ISS). Laboratory data ana-
lysed were FXM before or on the day of transplanta-
tion (using historic, recent or baseline serum), on 
3rd posttransplantation day (3rd PTd) and prospec-
tively thereafter (one to twice weekly), serum cre-
atinine (Scr) values and proteinuria.
Renal allograft biopsies were performed within 
two weeks posttransplantation whenever possible, 
and subsequently according to the evaluation of FXM 
histology and clinical follow up. Antibody mediated 
rejection (AMR) was defined by the presence of 
peritubular capillaritis in the renal allograft biopsy, 
diffuse peritubular capillary C4d deposits and circu-
lating anti -DSA.
 Biochemical analysis
T cell FXM was performed with an indirect immun-
ofluorescent technique (BD FACSCaliburTM) and results 
expressed as a relative number RN, obtained as a 
ratio of mean channel fluorescence of sample (FS) 
versus negative control sera (FC) (NR=FS/FC x 100), 
considering as positive result a NR higher than 150.
 Immunosuppression protocols
Immunosuppression with tacrolimus (FK) 0.05mg/
kg, mycophenolate mophetil (MMF) 500mg before 
transplantation and 1000mg after transplantation, 
and prednisolone (PDN) 20mg day, preceded by 
therapeutic induction with Tymoglobulin 1.5mg/kg 
and IVIG, was given to all patients. FK doses were 
adjusted to obtain a trough level of 10 -15 ng/ml 
during the first three months. MMF was used in a 
fixed dose of 500mg BO. All patients received pro-
phylactic treatment with valganciclovir, trimetoprim/
sulfametoxazole and isoniazid whenever indicated.
In the first nine patients (group A) IVIG 400mg/
kg/day was started pretransplantation and continued 
for five days, with Rituximab 375mg/m2 (RTX) intro-
duced only in presence of AMR.
The incidence of AMR observed (see results) 
prompted us in the subsequent 21 patients to employ 
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a more intense preemptive protocol (group B), with 
IVIG 2g/kg for 48h starting immediately before trans-
plantation and RTX 375 mg/m2 administered on 3rd 
PTd, whenever a positive FXM result was reported.
In both groups RTX and IVIG (from one to five 
administrations) were reintroduced in the presence 
of AMR, or in group B in the presence of persistent 
positive FXM or persistent positive peritubular C4d 
deposits. A total of 13 patients never received RTX, 
5 (55.6%) in group A and 8 (38.1%) in group B. 
Plasmapheresis was reserved for the most severe 
cases of AMR, particularly those requiring haemodi-
alysis, and employed in only five patients, four in 
group A and one in group B.
 Statistical analysis
The data are presented as mean ± SD values for 
normally distributed variables or as frequencies for 
categorical variables. Univariate analysis (Spearman 
correlation) and multivariate analysis (linear regres-
sion, confidence interval of 95%, with forward 
method) were performed using the SPSS 15.0 system 
(SPSS Inc., Chicago, IL) and a p<0.05 was considered 
statistically significant.
 RESULTS
Table I shows the clinical characteristics and 
evolution of our population, separately indicating 
results for patients with positive FXM prior to trans-
plantation, and for the whole population.
Despite all patients having a negative CDC cross-
match, with recent serum and absence of previ-
ously identified anti class I DSA, T cell FXM per-
formed in the first 24h posttransplantation with 
pretransplant serum (historic, recent or baseline) 
were positive in 19/29 patients, and negative in 9/29. 
In one patient FXM results were only obtained after 
the 3rd PTd. An additional patient had a positive 
FXM with serum obtained at the 3rd PTd.
We also determined the evolution of FXM after 
the 3rd PTd: it was positive in 17/27 patients, 
whereas 82.4% of these patients (14/17) had a pre-
vious positive FXM (Fisher=0.04). FXM were positive 
after the 3rd PTd in 64.7% of patients in group B 
and in 75% of those in group A (p>0.05).
Acute rejection episodes occurred in 16 (53.3%) 
patients: four recipients presented with acute 
decreases in renal function in the absence of 
obstruction, toxicity, etc., and biopsies were not 
available at the time of acute deterioration of renal 
function (two patients had intraperitoneal allografts); 
the other 12 patients had biopsy proven acute rejec-
tion episodes: eight AMR, two borderline, one Banff 
IIa and one Banff Ia. AMR occurred in 44.4% (4/9) 
of patients included in group A, and in 19% (4/21) 
of patients in group B (Table II). AMR was observed 
in early posttransplant period, and usually pro-
gressed very rapidly. Using linear regression, AMR 
was correlated with positive FXM before transplanta-
tion or until the 3rd PTd (p=0.03, CI 0.06 to 0.8), 
with positive FXM after the 3rd PTd (p=0.03, CI 0.05 
Table I
Clinical characteristics of the population
Variables
FXM + historic/ 
recent/baseline
All patients
Number (n) 65.5% (19/29) 100% (30)
Recipient age (yr) 45.1±11.6 46.9±11.2
Female gender (%) 68.4% (13) 60% (16)
Caucasian race (%) 78.9% (15) 80% (24)
Mean HD time (month) 129.6±64.5 140±69.3
Retransplantation (%) 57.9% (11) 40% (14)
Deceased donor (%) 100% (19) 100% (30)
Donor age (yr) 44±9 42.9±11.7
Donor Scr (mg/dl) 1±0.5 1.2±0.6
Mean cold ischaemia time (hrs) 17.7±3.8 17.6±3.7
Delayed graft function (%) 26.3% (5) 33.3% (10)
Preemptive IVIG/RTX for previous 
FXM + (Group B) 
68.4% (13/19) 70% (21/30)




















Follow up (month) 11.3±6.6 11.7±6











Patient survival 94.7% (18) 96.7% (29/30)
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to 0.8) and was inversely correlated with graft sur-
vival (p=0.04, CI  -0.9 to  -0.005).
Mean allograft survival was 12.2±5.5 months, 16 
grafts surviving for more than 12 months. Allograft 
survival was better in group B vs. A (81% vs. 66.6%) 
and in patients with negative vs. positive FXM (89% 
vs. 73%), but without statistical significance (p>0.05). 
There were two surgical losses (one in each group) 
and one patient died. Using linear regression, allo-
graft survival was inversely correlated not only with 
AMR episodes, but also with haemodialysis need 
posttransplant (p<0.001, CI  -0.8 to  -0.3) and with a 
positive FXM higher than 5000 on the 3rd PTd 
(p=0.03, CI  -1.6 to  -0.1). No AMR was observed after 
the third month (up to one year in 16 surviving 
recipients). Renal function in the 23 patients with 
functioning allograft was excellent up to end of fol-
low up (creatinine 1.3±0.6 mg/dl).
 DISCUSSION
In highly sensitised patients, transplant rates are 
extremely low due to the additional immunological 
barrier, with increased rejection risk and poor allo-
graft survival1,3,4. Indeed, more than half of our 
study population had at least one rejection episode, 
mostly AMR episodes, and these were correlated 
with positive FXM and with loss of kidney function. 
As stated, severe AMR with rapid loss of diuresis 
and renal function were treated as rapidly as pos-
sible for removal of antibodies, and in these cases 
plasmapheresis was employed. Patients with less 
severe changes in renal function, maintaining urinary 
output, were treated primarily with IVIG and RTX, 
and only with plasmapheresis if renal function or 
diuresis continued to deteriorate in the presence of 
highly positive FXM and renal lesions (not only C4d 
presence).
Improving results in highly sensitised patients is 
challenging. A few approaches have been employed, 
including anti B cell antibody treatment (RTX) or 
administration of IVIG5, but their use as posttrans-
plant prophylactic agents is currently under study2. 
Our results indicate that the use of IVIG plus RTX 
is an acceptable approach in these sensitised 
patients. In fact, and despite the majority of our 
patients developing positive T cell FXM after trans-
plantation, we have obtained an allograft survival 
of 81% (including one surgical loss) when employ-
ing a preemptive strategy (group B) with RTX 
introduced early in the post transplantation period, 
before signs of AMR, and continued (together with 
IVIG) until resolution of PTC C4d deposits or sig-
nificant decrease in FXM. This preemptive approach 
with RTX and IVIG allowed us to reduce the inci-
dence of AMR by more than 50% in this high risk 
population with PRA in excess of 70% and positive 
T cell FXM. No major complications were observed 
with the use of RTX. Only one patient died and had 
not been treated with RTX.
It remains to be determined if administration of 
RTX at the time of transplantation could improve 
our results, but it is now our policy to introduce it 
as soon as positive FXM becomes available. Concern-
ing the flow cytometric results, our preliminary data 
points to the relevance of post transplant antibodies 
detected with flow cytometry. The higher NR value 
on 3rd PTd may predict allograph loss. Low NR val-
ues may not predict allograft loss, but allograft 
function may be compromised in later evaluations. 
The role of alloantibodies detected by means of 
cytometric techniques must be discussed concerning 
its serum concentration and complement activating 
capacity.
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Table II
Clinical characteristics according to the induction protocol used
Variables Group A Group B
Number (n) 9 21
Recipient age (yr) 45.8±8.9 47.4±12.2
Female gender (%) 55.6 61.9
Caucasian race (%) 77.7 90.5
Mean HD time (month) 128.5±84.6 144.9±63.4
Retransplantation (%) 33.3 52.4
Donor age (yr) 41.2±13.8 43.7±10.9
Donor Scr (mg/dl) 1.0±0.4 1.3±0.7
HLA mismatches 4.5±1.2 4.6±1.2
Mean cold ischaemia time (hr) 17.8±3.3 17.5±3.9
FXM + historic/recent/baseline 66.7% (6/9) 65% (13/20)
FXM + after 3rd PTd (%) 75% (6/8) 64.7% (11/17)
Delayed graft function (%) 33.3 33.3
AMR (%) 44.4% (4/9) 19% (4/21)
Follow up (month) 8.1±5.5 6.4±3.4
Mean final Scr (mg/dl) 4.2±4.2 1.2±0.3
Allograft survival (%) 66.6%% (6/9) 81% (17/21)
HD (haemodialysis); Scr (serum creatinine); FXM (flow cytometric crossmatch); 
PTd (Posttransplantation day); AMR (antibody mediated rejection)
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Our protocol in group B is very similar to a recent 
rapid desensitisation protocol6, with the difference that 
RTX is started only after transplantation, whenever a 
positive FXM is identified. Taken together our results 
and those published by Voo et al.6 seem to indicate 
the efficacy of the association of IVIG and RTX.
There are some limitations to our study. First of 
all, it is a retrospective study. Secondly, we had to 
modify our approach after the first nine patients due 
to an unacceptable incidence of severe AMR, not 
allowing a clear comparison with patients included in 
group B. Thirdly, our conclusions must be very tenta-
tive as this is not a randomised study, but instead a 
sequential study. However, our preemptive approach 
was highly successful, preventing the development of 
AMR in 80% of patients (group B) despite the pres-
ence of early and persistent positive T cell flow 
crossmatch, and resulting in an allograft survival of 
81% (including one surgical loss) up to more than one 
year posttransplant in these very high risk patients.
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